V-Card | Print | PDF | Email Page

Lin Yu Ph.D.


(T) +1.858.314.1128
(F) +1.844.345.3178


  • University of San Diego (J.D. 2011); University of California, San Diego (Ph.D. in Medicinal Chemistry 1991); Sun Yat-Sen University (B.S. in Chemistry 1984; recipient of Doering's China-U.S. Chemistry Graduate Program (CGP))

Bar Admissions

  • California and registered to practice before the U.S. Patent and Trademark Office

Dr. Lin Yu's practice focuses on global patent portfolio development, management, and enforcement in the areas of biotechnology, pharmaceuticals, and polymer chemistry. Lin has devised global patent strategies for small molecule drugs, therapeutic antibodies, antibody drug conjugates, and nucleotide therapies. He also has advised established and emerging pharmaceutical and biotechnology companies on the strategic planning and acquisition of intellectual property portfolios. His experience includes patent portfolio evaluations and due diligence investigations, including patentability, invalidity, infringement, and freedom-to-operate investigations.

Representative clients include BioMarin Pharmaceutical, Celgene Corporation, Chevron Corporation, Puma Biotechnology, Inc., and Takeda Pharmaceutical Company. Pharmaceutical products for which Lin has experience include: Alunbrig®, Kuvan®, Nerlynx®, Pomalyst®, and Revlimid®.

In 2016, Lin was a member of the trial team that achieved the record-breaking patent infringement verdict for Idenix Pharmaceuticals (a subsidiary of Merck & Co.), the largest infringement verdict in U.S. history. After a two-week trial, the jury ordered Gilead Sciences to pay $2.54 billion in damages for sales of sofosbuvir-based medicines, including Sovaldi and Harvoni, for its infringement of an Idenix patent related to the treatment of patients with hepatitis C virus (HCV) infection.

Before joining Jones Day in 2007, Lin co-founded Triad Therapeutics, served as vice president of chemistry and biochemistry, and oversaw the development of its small molecule kinase inhibitors for rheumatoid arthritis, which was later licensed to Novartis.

Lin Yu